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Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205 S199or 4-hour pre-exposure to SAHA followed by washing then
addition of [Clad+Gem+Bu] resulted in 40%, and 46% inhi-
bition, respectively (P ¼ 0.005). These results underscore
the importance of optimizing the sequence of drug expo-
sure. Our results provide a basis for using [Clad+Gem+Bu]
as a pre-transplant conditioning regimen for lymphoma
patients undergoing HSCT, and further addition of an
epigenetic modiﬁer, such as SAHA, may play a role as a
sensitizer to optimize the efﬁcacy of the chemotherapy
regimen.261
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Introduction: Studies suggest that the clonogenic cell in
Multiple Myeloma (MM) is a post-germinal center B-cell
expressing CD20, which makes it a potential target for
antibody therapy. 90Y-Zevalin (ibritumomab tiuxetan)
combines an anti-CD20 antibody with the radioisotope
yttrium-90, which has the potential to kill not only a tar-
geted CD20+ cell, but also neighboring plasma cells which
may not express CD20. This phase II trial evaluated the
safety and efﬁcacy of 90-Zevalin given prior to planned high
dose chemotherapy (melphalan 200mg/m2) and ASCT to
patients with incomplete response to prior chemotherapy
for MM.
Methods: Patients received a cold dose of rituximab
250mg/m2 followed by single dose of 0.4mCi/kg 90Y-Zevalin
(max 32mCi) at least 4weeks following last chemotherapy for
MM, corresponding to day -14 prior to ASCT. 111In-Zevalin
was given one week prior for imaging to conﬁrm expected
biodistribution. At least 14 days separated the outpatient
administration of 90Y-Zevalin and reinfusion of autologous
stem cells to allow for sufﬁcient 90Y decay. Response was
assessed andmelphalan administered on day -2 prior to ASCT
and again 90 days after ASCT. This non-randomized study
employed a Simon two-stage, minmax design. All patients
who received the therapeutic dose of 90Y-Zevalin were
included in theanalysis. Responsewas scoredaccording to the
criteria of Blade J, et al. (1998)
Results: Six patients received 90Y-Zevalin followed by
melphalan and ASCT (5 were male, age range 53-68, 2 were
second transplants). Median time to engraftment was 12
days (range 8-21). Four patients had measurable disease at
entry and were strictly evaluable for response. One patient
achieved partial response (PR) after 90Y-Zevalin and very
good PR after ASCT. Two patients achieved stable disease
(SD) after 90Y-Zevalin; and PR and complete response
respectively after ASCT. The fourth patient had progressive
disease (PD) after 90Y-Zevalin and SD after ASCT. A seventh
patient received 90Y-Zevalin with delayed ASCT in an initial
iteration of the protocol, with PD documented at >10 weeks.
Seven patients were evaluable for toxicity. There was no
infusion related toxicity. Four patients had peri-transplant
bacterial infections: line associated septic thrombosis,
bacteremia without source x 2, and peri-rectal abscessassociated with delayed engraftment prompting infusion of
back-up stem cells on day +19 and granulocytes.
Conclusion: Although the pre-speciﬁed response threshold
was reached in stage I; the modest response rate associated
with the high expense of radioimmunotherapy and concern
for a possible increase in peri-ASCT bacterial infections limits
enthusiasm for further study.
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Second autologous stem cell transplant (ASCT) is a treatment
option for multiple myeloma (MM) patients (pts) who have
disease progression after ﬁrst ASCT. Outcomes of second
ASCT in pts with renal dysfunction (RD) have not been
described.
We identiﬁed 18 pts at our institution who underwent a
second ASCT for relapsed MM and had evidence of RD
(creatinine clearance  60ml/min/1.73m2). Pts who under-
went a planned tandem transplant were excluded from this
analysis. Patient characteristics are shown in Table 1. Ten pts
received one chemotherapy (CT) regimen while nine pts
received two or more CT regimens between ﬁrst and second
ASCT. The CT regimens used between ﬁrst and second
transplant included Imid based (n¼6), proteosome inhibitor
based (n¼3) and combination of both (n¼9). Approximately
half of the pts had progressive disease at the time of second
ASCT. Median creatinine clearance at the time of second
ASCT was 43.5 ml/min/1.73m2. One pt was dialysis depen-
dent. All pts received G-CSF 5mg/Kg from day + 6 till ANC was
1500/ mL.
Median follow up post second ASCT was 17.1 months
(range, 2.4-100). One pt died at day 74 due to multi organ
failure. Of 17 evaluable pts at day 100, twelve had an up-
grade from the disease response category achieved with
the last regimen used prior to second ASCT while ﬁve pts
had stable disease response. Three pts received mainte-
nance therapy after the second ASCT with bortezomib(n¼2)
and lenalidomide (n¼1). Figure 1 shows the overall survival
(OS) after second ASCT and Figure 2 shows the relapse free
survival (RFS) from ﬁrst and second ASCT. After the second
ASCT, the median OS was 27 months while the median RFS
was 22.2 months (median RFS after ﬁrst ASCT was 24
months).
The transplant related mortality of these pts was not higher
than expected and the median RFS of about 2 years makes
the option of second ASCT in this group of patients a valuable
treatment modality and is comparable to reported outcomes
after second ASCT. In addition, the RFS after second ASCTwas
